Общедоступные статьи - Jack RothПодробнее...
5 статей недоступны нигде
Проверить
Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection
N Deboever, DJ McGrail, Y Lee, HT Tran, KG Mitchell, MB Antonoff, ...
Lung Cancer 164, 69-75, 2022
Финансирование: US National Institutes of Health
Проверить
Pulmonary resection for tissue harvest in adoptive tumor‐infiltrating lymphocyte therapy: Safety and feasibility
EM Corsini, KG Mitchell, N Zhou, C Bernatchez, MA Forget, CL Haymaker, ...
Journal of surgical oncology 124 (4), 699-703, 2021
Финансирование: US National Institutes of Health
Проверить
Multifunctional tumor-targeted nanoparticles for lung cancer
S Kuroda, T Yokoyama, JO Tam, AW Scott, LL Ma, M Shanker, J Jin, ...
Pulm Nanomed, 15-44, 2013
Финансирование: US National Institutes of Health
Проверить
Use of telomere length in peripheral leukocytes to predict risk of recurrence in patients with early-stage non-small cell lung cancer after curative resection.
ES Kim, AA Vaporciyan, J Xing, M Huang, MR Spitz, SM Lippman, J Gu, ...
Journal of Clinical Oncology 28 (15_suppl), 7031-7031, 2010
Финансирование: US National Institutes of Health
Проверить
Tumour‐Suppressor Gene Therapy
B Fang, JA Roth
Viral Therapy of Cancer, 229-239, 2008
Финансирование: US National Institutes of Health
186 статей доступны в некоторых источниках
Проверить
Somatic mutations affect key pathways in lung adenocarcinoma
L Ding, G Getz, DA Wheeler, ER Mardis, MD McLellan, K Cibulskis, ...
Nature 455 (7216), 1069-1075, 2008
Финансирование: US National Institutes of Health
Проверить
Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials
JY Chang, S Senan, MA Paul, RJ Mehran, AV Louie, P Balter, HJM Groen, ...
The lancet oncology 16 (6), 630-637, 2015
Финансирование: US National Institutes of Health, Netherlands Organisation for Health …
Проверить
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
CM Gay, CA Stewart, EM Park, L Diao, SM Groves, S Heeke, BY Nabet, ...
Cancer cell 39 (3), 346-360. e7, 2021
Финансирование: US Department of Defense, US National Institutes of Health, LUNGevity …
Проверить
Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial
T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ...
Nature medicine 27 (3), 504-514, 2021
Финансирование: US National Institutes of Health
Проверить
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
X Le, S Puri, MV Negrao, MB Nilsson, J Robichaux, T Boyle, JK Hicks, ...
Clinical Cancer Research 24 (24), 6195-6203, 2018
Финансирование: US National Institutes of Health
Проверить
Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy
A Pataer, N Kalhor, AM Correa, MG Raso, JJ Erasmus, ES Kim, ...
Journal of Thoracic Oncology 7 (5), 825-832, 2012
Финансирование: US National Institutes of Health
Проверить
Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA
R Huschka, A Barhoumi, Q Liu, JA Roth, L Ji, NJ Halas
ACS nano 6 (9), 7681-7691, 2012
Финансирование: US National Institutes of Health
Проверить
Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer
CA Stewart, CM Gay, Y Xi, S Sivajothi, V Sivakamasundari, J Fujimoto, ...
Nature cancer 1 (4), 423-436, 2020
Финансирование: US Department of Defense, US National Institutes of Health
Проверить
miR-93, miR-98, and miR-197 Regulate Expression of Tumor Suppressor Gene FUS1
L Du, JJ Schageman, MC Subauste, B Saber, SM Hammond, L Prudkin, ...
Molecular Cancer Research 7 (8), 1234-1243, 2009
Финансирование: US National Institutes of Health
Проверить
Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non–small-cell lung cancer
JY Chang, PA Balter, L Dong, Q Yang, Z Liao, M Jeter, MK Bucci, ...
International Journal of Radiation Oncology* Biology* Physics 72 (4), 967-971, 2008
Финансирование: US National Institutes of Health
Проверить
Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”
JY Chang, QQ Li, QY Xu, PK Allen, N Rebueno, DR Gomez, P Balter, ...
International Journal of Radiation Oncology* Biology* Physics 88 (5), 1120-1128, 2014
Финансирование: US National Institutes of Health
Проверить
Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified …
JY Chang, RJ Mehran, L Feng, V Verma, Z Liao, JW Welsh, SH Lin, ...
The Lancet Oncology 22 (10), 1448-1457, 2021
Финансирование: US National Institutes of Health
Проверить
Angular Analysis of the Decay
R Aaij, CA Beteta, T Ackernley, B Adeva, M Adinolfi, H Afsharnia, ...
Physical Review Letters 126 (16), 161802, 2021
Финансирование: US National Science Foundation, US Department of Energy, Swiss National …
Проверить
Phase I clinical trial of systemically administered TUSC2 (FUS1)-nanoparticles mediating functional gene transfer in humans
C Lu, DJ Stewart, JJ Lee, L Ji, R Ramesh, G Jayachandran, MI Nunez, ...
PloS one 7 (4), e34833, 2012
Финансирование: US National Institutes of Health
Проверить
Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo
J Meng, B Dai, B Fang, BN Bekele, WG Bornmann, D Sun, Z Peng, ...
PloS one 5 (11), e14124, 2010
Финансирование: US National Institutes of Health
Информация о публикациях и финансировании собрана автоматически.